Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640169 | 0.92 | AOC3 (0.44) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL10441226 | 0.90 | AOC3 (0.42) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL29688552 | 0.89 | MAOB (0.49) | AOC3MAPTSLC6A3SLC6A4MAOB | |
| SCHEMBL1237690 | 0.89 | MAOB (0.49) | AOC3MAPTSLC6A3SLC6A4MAOB | |
| SCHEMBL5584506 | 0.87 | AOC3 (0.40) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL7203954 | 0.84 | HRH4 (0.53) | CHRNA7 | |
| SCHEMBL6087786 | 0.84 | SMYD3 (0.42) | AOC3NPC1RAB9ALOXL2FLT3 | |
| Hydrochloric Acid SCHEMBL8023167 | 0.83 | SLC6A3 (0.38) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL7968720 | 0.82 | HTR2A (0.47) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL12993141 | 0.82 | CYP2A6 (0.44) | FLT3CYP2A6CHRNA7SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105198888-A | 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone, derivative and synthetic method of 2,3a-disubstituted-3H-pyrazole[1,5-a]indole-4(3aH)-ketone and derivative | UNIV XIANGTAN | 2015-12-30 | — | — | CN | claimed |
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | claimed |
| JP-2006514009-A | — | — | 2006-04-27 | — | — | JP | claimed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | claimed |
| EP-1585751-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | Celmed Oncology (USA), Inc. (CA) | 2005-10-19 | — | — | EP | claimed |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | NEWBIOTICS, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| US-12509441-B2 | Compounds used as kinase inhibitors and application thereof | TYK MEDICINES (ZHENGZHOU), INC. (CN) | 2025-12-30 | — | — | US | disclosed |
| CN-119019383-A | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118662655-A | Compound, pharmaceutical composition, preparation method and application thereof | 安迪高生物制药有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118420511-A | Synthesis method of 2-alkyl indole | 南京工业大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-115175902-B | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-113179640-B | Nitrogen-containing polycyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-1998025898-A1 | SECO PRECURSORS OF CYCLOPROPYLINDOLINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998011101-A2 | CONDENSED N-ACLYINDOLES AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5646298-A | Cyclopropylindole prodrugs | PROCORON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997007101-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509441-B2 | Compounds used as kinase inhibitors and application thereof | ERBB2, ERBB3, BRAF | AOC3 3992/4885NPC1 1446/4885RAB9A 637/4885 |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | AOC3 3535/4885NPC1 2823/4885RAB9A 1928/4885 |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | AOC3 3523/4885NPC1 2399/4885RAB9A 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.